{"id":7893,"date":"2022-11-16T13:00:29","date_gmt":"2022-11-16T12:00:29","guid":{"rendered":"http:\/\/www.seventure.fr\/?p=7893"},"modified":"2022-11-16T13:00:29","modified_gmt":"2022-11-16T12:00:29","slug":"enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022","status":"publish","type":"post","link":"https:\/\/www.seventure.fr\/en\/enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022\/","title":{"rendered":"Enterome announces presentation of data from ongoing Phase 1\/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[105],"tags":[],"class_list":["post-7893","post","type-post","status-publish","format-standard","hentry","category-microbiome-nutrition-foodtech-lifestyle"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Enterome announces presentation of data from ongoing Phase 1\/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022 | Seventure<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/en\/enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ana Salas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/en\/enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022\/\",\"url\":\"https:\/\/www.seventure.fr\/en\/enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022\/\",\"name\":\"Enterome announces presentation of data from ongoing Phase 1\/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022 | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2022-11-16T12:00:29+00:00\",\"author\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/f946a5619a12f5415e660b8de142e495\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/en\/enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/en\/enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enterome announces presentation of data from ongoing Phase 1\/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/f946a5619a12f5415e660b8de142e495\",\"name\":\"Ana Salas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6bd15ac43de868d8defc5e4c6f7146da38bec786e08467e81680cd5ac0a24d5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6bd15ac43de868d8defc5e4c6f7146da38bec786e08467e81680cd5ac0a24d5?s=96&d=mm&r=g\",\"caption\":\"Ana Salas\"},\"url\":\"https:\/\/www.seventure.fr\/en\/author\/ana-salas\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enterome announces presentation of data from ongoing Phase 1\/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022 | Seventure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/en\/enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022\/","twitter_misc":{"Written by":"Ana Salas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/en\/enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022\/","url":"https:\/\/www.seventure.fr\/en\/enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022\/","name":"Enterome announces presentation of data from ongoing Phase 1\/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022 | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2022-11-16T12:00:29+00:00","author":{"@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/f946a5619a12f5415e660b8de142e495"},"breadcrumb":{"@id":"https:\/\/www.seventure.fr\/en\/enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/en\/enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/en\/enterome-announces-presentation-of-data-from-ongoing-phase-1-2-trial-of-its-peptide-based-immunotherapy-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sno-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Enterome announces presentation of data from ongoing Phase 1\/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/f946a5619a12f5415e660b8de142e495","name":"Ana Salas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6bd15ac43de868d8defc5e4c6f7146da38bec786e08467e81680cd5ac0a24d5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6bd15ac43de868d8defc5e4c6f7146da38bec786e08467e81680cd5ac0a24d5?s=96&d=mm&r=g","caption":"Ana Salas"},"url":"https:\/\/www.seventure.fr\/en\/author\/ana-salas\/"}]}},"_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/7893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=7893"}],"version-history":[{"count":1,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/7893\/revisions"}],"predecessor-version":[{"id":7896,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/7893\/revisions\/7896"}],"wp:attachment":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media?parent=7893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/categories?post=7893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/tags?post=7893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}